Clinical Trial Update: Immunogenicity and Safety of a Monovalent Glycoprotein-Conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the immunogenicity and safety of a monovalent glycoprotein-conjugated Hib vaccine (Diphtheria toxin CRM197) in healthy children aged 13…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilus Influenzae Type Infection

Drugs mentioned

• Hib vaccine (Diphtheria toxin CRM197-conjugated, monovalent glycoprotein-conjugated) (Haemophilus influenzae type b vaccine, glycoprotein-conjugated with diphtheria toxin CRM197)

Snippet

Sponsor: Novartis Vaccines | Conditions: Haemophilus Influenzae Type b (Hib) Infection | Phase 3 | Status: COMPLETED